Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 10Specimen Handling 9Cisplatin 7pembrolizumab 4Radiation 4Platinum 4Biopsy 41,2-diaminocyclohexaneplatinum II citrate 4Surgical Procedures, Operative 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Cetuximab 3toripalimab 2cemiplimab 2Interviews as Topic 2Docetaxel 2Chemoradiotherapy 2Carboplatin 2sacituzumab govitecan 1merphos 1ipatasertib 1cobimetinib 1cabozantinib 1X-Rays 1Vemurafenib 1Tretinoin 1Transurethral Resection of Bladder 1Taxes 1Surveys and Questionnaires 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Laryngeal Neoplasms × (225)Ac-DOTA-c(RGDyK) × Clear all
NCT06589804 2026-06-03

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

National Cancer Institute (NCI)

Phase 3 Recruiting
158 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡